By simultaneously targeting multiple pathways including inhibition of cholesterol synthesis via HMGCR, reduction of lipoprotein secretion via APOB, preservation of LDLR through PCSK9 suppression, enhancement of LDLR expression and activation of lipid oxidation through PPAR-α, charantin offers a holistic approach to managing dyslipidemia. This evidence concerns the gene PCSK9 and metabolic syndrome.